In accordance, E-cadherin was found to be more often and prominently expressed in endometrioid adenocarcinoma than in serous papillary or clear cell tumors [131,139,140], and a high E-cadherin level has been associated with reduced mortality, disease progression, and disease recurrence rate and thus is associated with a better prognosis [141]. The gene discussed is CDH1; the disease is endometrioid adenocarcinoma.